Streetbeat News

Stock Prices

BCDA

BioCardia (NASDAQ:BCDA) reported Q4 earnings with an EPS of $-0.09, beating estimates by 18.0% but with a revenue decrease of $93 thousand from the previous year. The company's past earnings performance shows mixed results with a notable share price drop of 6.0% after missing EPS estimates last quarter.

Portfolio Pulse from Benzinga Insights

March 27, 2024 | 8:10 pm

RUM

Rumble reported a 16% increase in Monthly Active Users (MAUs) to 67 million in Q4 from Q3.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 8:09 pm

MLKN

MillerKnoll reported Q3 2024 adjusted EPS of $0.45, surpassing the $0.44 estimate, but its sales of $872.3M fell short of the $909.5M forecast, marking an 11.41% decrease from the previous year.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 8:08 pm

FUL

H.B. Fuller (NYSE:FUL) reported Q1 adjusted earnings of $0.67 per share, surpassing the consensus estimate of $0.64, a 21.82% increase from last year. However, sales of $810.42M fell short of the $825.03M estimate, marking a slight 0.15% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 8:06 pm

BCDA

BioCardia (NASDAQ:BCDA) reported Q4 earnings with a per-share loss of $(0.09), beating the $(0.11) estimate, marking an 18.18% improvement. However, their quarterly sales of $13.00K fell short of the $90.00K estimate by 85.56%, representing an 87.74% decrease from the previous year.

Portfolio Pulse from dijoy@benzinga.com

March 27, 2024 | 8:06 pm

DRRX

Durect Corporation (NASDAQ:DRRX) reported Q4 2023 earnings with a GAAP EPS of $(0.10), surpassing the $(0.33) estimate, and sales of $2.669M, exceeding the $2.477M estimate. However, this represents a 19.49% decrease in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 8:05 pm

ROP

Over the past 10 years, Roper Techs (NASDAQ:ROP) has produced an average annual return of 15.29%, outperforming the market by 4.54% annually. With a current market capitalization of $59.50 billion, a $1000 investment in ROP 10 years ago would now be worth $4,182.65. This showcases the significant impact of compounded returns on investment growth over time.

Portfolio Pulse from Benzinga Insights

March 27, 2024 | 8:00 pm

CPRT

Over the past 10 years, Copart (NASDAQ:CPRT) has significantly outperformed the market, yielding an average annual return of 28.75%. A $100 investment in CPRT a decade ago would now be worth $1,257.38. This showcases the impact of compounded returns on investment growth over time. Copart's current market capitalization stands at $55.56 billion.

Portfolio Pulse from Benzinga Insights

March 27, 2024 | 8:00 pm

NIO

XPEV

XPeng shares are trading lower, potentially in sympathy with NIO, which saw a decline after reducing its delivery outlook.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 7:54 pm

VERA

Vera Therapeutics' stock price increased following Guggenheim's decision to maintain a Buy rating and raise its price target from $27 to $56.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 7:53 pm